R E V I E W Open Access
International Society of Sports Nutrition
position stand: safety and efficacy of
creatine supplementation in exercise, sport,
Richard B. Kreider
, Douglas S. Kalman
, Jose Antonio
, Tim N. Ziegenfuss
, Robert Wildman
, Rick Collins
Darren G. Candow
, Susan M. Kleiner
, Anthony L. Almada
and Hector L. Lopez
Creatine is one of the most popular nutritional ergogenic aids for athletes. Studies have consistently shown that creatine
supplementation increases intramuscular creatine concentrations which may help explain the observed improvements
in high intensity exercise performance leading to greater training adaptations. In addition to athletic and exercise
improvement, research has shown that creatine supplementation may enhance post-exercise recovery, injury prevention,
thermoregulation, rehabilitation, and concussion and/or spinal cord neuroprotection. Additionally, a number of clinical
applications of creatine supplementation have been studied involving neurodegenerative diseases (e.g., muscular
dystrophy, Parkinson’s, Huntington’s disease), diabetes, osteoarthritis, fibromyalgia, aging, brain and heart ischemia,
adolescent depression, and pregnancy. These studies provide a large body of evidence that creatine can not only
improve exercise performance, but can play a role in preventing and/or reducing the severity of injury, enhancing
rehabilitation from injuries, and helping athletes tolerate heavy training loads. Additionally, researchers have identified a
number of potentially beneficial clinical uses of creatine supplementation. These studies show that short and long-term
supplementation (up to 30 g/day for 5 years) is safe and well-tolerated in healthy individuals and in a number of patient
populations ranging from infants to the elderly. Moreover, significant health benefits may be provided by ensuring
habitual low dietary creatine ingestion (e.g., 3 g/day) throughout the lifespan. The purpose of this review is to provide an
update to the current literature regarding the role and safety of creatine supplementation in exercise, sport, and medicine
and to update the position stand of International Society of Sports Nutrition (ISSN).
Keywords: Ergogenic aids, Performance enhancement, Sport nutrition, Athletes, Muscular strength, Muscle power, Clinical
applications, Safety, Children, Adolescents
Creatine is one of the most popular nutritional ergogenic
aids for athletes. Studies have consistently shown that
creatine supplementation increases intramuscular creatine
concentrations, can improve exercise performance, and/or
improve training adaptations. Research has indicated that
creatine supplementation may enhance post-exercise recov-
ery, injury prevention, thermoregulation, rehabilitation, and
concussion and/or spinal cord neuroprotection. A number
of clinical applications of creatine supplementation have
also been studied involving neurodegenerative diseases
(e.g., muscular dystrophy, Parkinson’s, Huntington’s
disease), diabetes, osteoarthritis, fibromyalgia, aging, brain
and heart ischemia, adolescent depression, and pregnancy.
The purpose of this review is to provide an update to the
current literature regarding the role and safety of creatine
supplementation in exercise, sport, and medicine and to
update the position stand of International Society of Sports
Nutrition (ISSN) related to creatine supplementation.
* Correspondence: email@example.com
Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Department
of Health & Kinesiology, Texas A&M University, College Station, TX
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18
Creatine, a member of the guanidine phosphagen family, is
a naturally occurring non-protein amino acid compound
found primarily in red meat and seafood [1–4]. The major-
ity of creatine is found in skeletal muscle (~95%) with small
amounts also found in the brain and testes (~5%) [5, 6].
About two thirds of intramuscular creatine is phosphocrea-
tine (PCr) with the remaining being free creatine. The total
creatine pool (PCr + Cr) in the muscle averages about
120 mmol/kg of dry muscle mass for a 70 kg individual .
However, the upper limit of creatine storage appears to be
about 160 mmol/kg of dry muscle mass in most individuals
[7, 8]. About 1–2% of intramuscular creatine is degraded
into creatinine (metabolic byproduct) and excreted in the
urine [7, 9, 10]. Therefore, the body needs to replenish
about 1–3 g of creatine per day to maintain normal
(unsupplemented) creatine stores depending on muscle
mass. About half of the daily need for creatine is obtained
from the diet . For example, a pound of uncooked beef
and salmon provides about 1–2 g of creatine . The
remaining amount of creatine is synthesized primarily in
the liver and kidneys from arginine and glycine by the
enzyme arginine:glycine amidinotransferase (AGAT) to
guanidinoacetate (GAA), which is then methylated by
guanidinoacetate N-methyltransferase (GAMT) using
S-adenosyl methionine to form creatine (see Fig. 1) .
Some individuals have been found to have creatine
synthesis deficiencies due to inborn errors in AGAT,
GMAT and/or creatine transporter (CRTR) deficiencies
and therefore must depend on dietary creatine intake in
order to maintain normal muscle and brain concentra-
tions of PCr and Cr [13–19]. Vegetarians have been
reported to have lower intramuscular creatine stores (90–
110 mmol/kg of dry muscle) and therefore may observe
greater gains in muscle creatine content from creatine
supplementation [11, 13, 20, 21]. Conversely, larger ath-
letes engaged in intense training may need to consume 5–
10 g/day of creatine to maintain optimal or capacity whole
body creatine stores  and clinical populations may
need to consume 10–30 g/day throughout their lifespan
to offset creatine synthesis deficiencies and/or provide
therapeutic benefit in various disease states [13, 19, 23].
Phosphagens are prevalent in all species and play an im-
portant role in maintaining energy availability [1, 2, 24, 25].
a phosphoryl group (Pi) to form PCr through the enzym-
atic reaction of creatine kinase (CK). Wallimann and col-
leagues [26–28] suggested that the pleiotropic effects of Cr
are mostly related to the functions of CK and PCr (i.e.,
CK/PCr system). As adenosine triphosphate (ATP) is de-
graded into adenosine diphosphate (ADP) and Pi to pro-
vide free energy for metabolic activity, the free energy
released from the hydrolysis of PCr into Cr + Pi can be
used as a buffer to resynthesize ATP [24, 25]. This helps
maintain ATP availability particularly during maximal ef-
fort anaerobic sprint-type exercise. The CK/PCr system
also plays an important role in shuttling intracellular en-
ergy from the mitochondria into the cytosol (see Fig. 2).
The CK/PCr energy shuttle connects sites of ATP produc-
tion (glycolysis and mitochondrial oxidative phosphoryl-
ation) with subcellular sites of ATP utilization (ATPases)
[24, 25, 27]. In this regard, creatine enters the cytosol
through a CRTR [16, 29–31]. In the cytosol, creatine and
associated cytosolic and glycolytic CK isoforms help
Fig. 1 Chemical structure and biochemical pathway for creatine synthesis. From Kreider and Jung 
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 2 of 18
Fig. 2 Proposed creatine kinase/phosphocreatine (CK/PCr) energy shuttle. CRT = creatine transporter; ANT =adenine nucleotide translocator; ATP =
adenine triphosphate; ADP = adenine diphosphate; OP = oxidative phosphorylation; mtCK = mitochondrial creatine kinase; G = glycolysis; CK-g =
creatine kinase associated with glycolytic enzymes; CK-c =cytosolic creatine kinase; CK-a =creatine kinase associated with subcellular sites of ATP
utilization; 1 –4 sites of CK/ATP interaction. From Kreider and Jung 
Fig. 3 Role of mitochondrial creatine kinase (mtCK) in high energy metabolite transport and cellular respiration. VDAC = voltage-dependent anion
channel; ROS = reactive oxygen species; RNS = reactive nitrogen species; ANT = adenine nucleotide translocator; ATP = adenine triphosphate; ADP
= adenine diphosphate; Cr = creatine; and, PCr = phosphocreatine. From Kreider and Jung 
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 3 of 18
maintain glycolytic ATP levels, the cytosolic ATP/ADP ra-
tio, and cytosolic ATP-consumption . Additionally, cre-
atine diffuses into the mitochondria and couples with ATP
produced from oxidative phosphorylation and the adenine
nucleotide translocator (ANT) via mitochondrial CK (see
Fig. 3). ATP and PCr can then diffuse back into the cytosol
and help buffer energy needs. This coupling also reduces
the formation of reactive oxygen species (ROS) and can
therefore act as a direct and/or indirect antioxidant [32–
35]. The CK/PCr energy shuttle thereby connects sites of
ATP production (glycolysis and mitochondrial oxidative
phosphorylation) with subcellular sites of ATP utilization
(ATPases) in order to fuel energy metabolism [24, 25, 27].
In this way, the CK/PCr system thereby serves as an
important regulator of metabolism which may help explain
the ergogenic and potential therapeutic health benefits of
creatine supplementation [4, 27, 33, 36–45].
In a normal diet that contains 1–2 g/day of creatine,
muscle creatine stores are about 60–80% saturated.
Therefore, dietary supplementation of creatine serves to
increase muscle creatine and PCr by 20–40% (see Fig. 4.)
[7, 8, 10, 46–48]. The most effective way to increase
muscle creatine stores is to ingest 5 g of creatine mono-
hydrate (or approximately 0.3 g/kg body weight) four
times daily for 5–7 days [7, 10]. However, higher levels
of creatine supplementation for longer periods of time
may be needed to increase brain concentrations of creat-
ine, offset creatine synthesis deficiencies, or influence
disease states [13, 19, 23]. Once muscle creatine stores
are fully saturated, creatine stores can generally be main-
tained by ingesting 3–5 g/day, although some studies
indicate that larger athletes may need to ingest as much
as 5–10 g/day in order to maintain creatine stores [7, 8, 10,
46–48]. Ingesting creatine with carbohydrate or carbohydrate
and protein have been reported to more consistently promote
greater creatine retention [8, 22, 49, 50]. An alternative
supplementation protocol is to ingest 3 g/day of creatine
monohydrate for 28 days . However, this method
would only result in a gradual increase in muscle
creatine content compared to the more rapid loading
method and may therefore have less effect on exercise
performance and/or training adaptations until creatine
stores are fully saturated. Research has shown that
once creatine stores in the muscle are elevated, it
generally takes 4–6 weeks for creatine stores to re-
turn to baseline [7, 48, 51]. Additionally, it has been
recommended that due to the health benefits of
creatine, individuals should consume about 3 g/day of
creatine in their diet particularly as one ages . No
evidence has suggested that muscle creatine levels fall
below baseline after cessation of creatine supplemen-
tation; therefore, the potential for long-term suppres-
sion of endogenous creatine synthesis does not appear
to occur [22, 52].
The most commonly studied form of creatine in the
literature is creatine monohydrate . The uptake of
creatine involves the absorption of creatine into the
blood and then uptake by the target tissue . Plasma
levels of creatine typically peak at about 60 min after
oral ingestion of creatine monohydrate . An initial rise
in plasma creatine levels, followed by a reduction in
plasma levels can be used to indirectly suggest increased
uptake into the target tissue . However, the gold
standards for measuring the effects of creatine supple-
mentation on target tissues are through magnetic resonance
spectroscopy (MRS), muscle biopsy, stable isotope tracer
studies, and/or whole body creatine retention assessed by
Fig. 4 Approximate muscle total creatine levels in mmol/kg dry weight muscle reported in the literature for vegetarians, individuals following a
normal diet, and in response to creatine loading with or without carbohydrate (CHO) or CHO and protein (PRO). From Kreider and Jung 
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 4 of 18
measuring the difference between creatine intake and urinary
excretion of creatine .
Creatine is stable in solid form but not in aqueous so-
lution due to an intramolecular cyclization . Gener-
ally, creatine is converted to creatinine at higher rates
the lower the pH and the higher the temperature. For
example, research has shown that creatine is relatively
stable in solution at neutral pH (7.5 or 6.5). However,
after 3 days of storage at 25 °C, creatine degrades to cre-
atinine (e.g., 4% at pH 5.5; 12% at pH 4.5; and 21% at
pH 3.5) [53, 55]. The degradation of creatine into cre-
atinine over time is the main reason that creatine is sold
in solid form. However, this does not mean that creatine
is degraded into creatinine in vivo through the digestive
process. In this regard, the degradation of creatine to
creatinine can be reduced or halted be either lowering
the pH under 2.5 or increasing the pH . A very low
pH results in the protonation of the amide function of
the creatine molecule, thereby preventing the intra-
molecular cyclization . Therefore, the conversion of
creatine to creatinine in the gastrointestinal tract is min-
imal regardless of transit time; absorption into the blood
is nearly 100% [10, 53, 56, 57].
The vast majority of studies assessing the efficacy of
creatine supplementation on muscle phosphagen levels,
whole body creatine retention, and/or performance have
evaluated creatine monohydrate. Claims that different
forms of creatine are degraded to a lesser degree than
creatine monohydrate in vivo or result in a greater up-
take to muscle are currently unfounded . Clinical
evidence has not demonstrated that different forms of
creatine such as creatine citrate , creatine serum
, creatine ethyl ester , buffered forms of creatine
, or creatine nitrate  promote greater creatine re-
tention than creatine monohydrate .
Table 1 presents the reported ergogenic benefits of
creatine supplementation. A large body of evidence
now indicates that creatine supplementation increases
muscle availability of creatine and PCr and can there-
fore enhance acute exercise capacity and training
adaptations in adolescents [62–66], younger adults
[61, 67–77] and older individuals [5, 40, 43, 78–85].
These adaptations would allow an athlete to do more
work over a series of sets or sprints leading to greater
gains in strength, muscle mass, and/or performance
due to an improvement in the quality of training.
Table 2 presents the types of sport events in which
creatine supplementation has been reported to bene-
fit. Creatine supplementation has primarily been rec-
ommended as an ergogenic aid for power/strength
athletes to help them optimize training adaptations or
athletes who need to sprint intermittently and recover
during competition (e.g., American football, soccer,
basketball, tennis, etc.). After creatine loading, per-
formance of high intensity and/or repetitive exercise
is generally increased by 10–20% depending on the
Benefits have been reported in men and women, al-
though the majority of studies have been conducted on
men and some studies suggest that women may not
see as much gain in strength and/or muscle mass
during training in response to creatine supplementa-
tion [20, 51, 64, 86–90]. However, as will be de-
scribed below, a number of other applications in
Table 1 Potential ergogenic benefits of creatine
•Increased single and repetitive sprint performance
•Increased work performed during sets of maximal effort muscle
•Increased muscle mass & strength adaptations during training
•Enhanced glycogen synthesis
•Increased anaerobic threshold
•Possible enhancement of aerobic capacity via greater shuttling
of ATP from mitochondria
•Increased work capacity
•Greater training tolerance
Adapted from Kreider and Jung 
Table 2 Examples of sport events that may be enhanced by
•Track sprints: 60–200 m
•Swim sprints: 50 m
Increased PCr Resynthesis
Reduced Muscle Acidosis
•Water Sports (e.g., Rowing, Canoe, Kayak, Stand-Up Paddling)
•Swim events: 100, 200 m
•Track events: 400, 800 m
•Combat Sports (e.g., MMA, Wrestling, Boxing, etc.)
•Interval Training in Endurance Athletes
Increased Body Mass/Muscle Mass
•Combat Sports (e.g., MMA, Wrestling, Boxing, etc.)
•Track/Field events (Shot put; javelin; discus; hammer throw)
Adapted from Williams, Kreider, and Branch 
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 5 of 18
sport may benefit athletes involved in high intensity
intermittent and endurance events as well. In terms
of performance, the International Society of Sports
Nutrition (ISSN) has previously concluded in its pos-
ition stand on creatine supplementation that creatine
monohydrate is the most effective ergogenic nutri-
tional supplement currently available to athletes in
terms of increasing high-intensity exercise capacity
and lean body mass during training [5, 78]. Recent
position stands by the American Dietetic Association,
Dietitians of Canada, and the American College of
Sports Medicine on nutrition for athletic performance
all drew similar conclusions [91, 92]. Thus, a wide-
spread consensus now exists in the scientific commu-
nity that creatine supplementation can serve as an ef-
fective nutritional ergogenic aid that may benefit
athletes involved in numerous sports as well as indi-
viduals involved in exercise training.
Prevalence of use in sport
Creatine is found in high amounts in the food supply
and therefore its use is not banned by any sport
organization although some organizations prohibit
provision of some types of dietary supplements to ath-
letes by their teams [5, 53, 78, 91, 92]. In these instances,
athletes can purchase and use creatine on their own
without penalty or violation of their banned substance
restrictions. Americans consume over four million kilo-
grams (kg) a year of creatine with worldwide use much
higher . The reported prevalence of creatine use
among athletes and military personnel in survey-based
studies has generally been reported to be about 15–40%
[93–101], with use more common in male strength/
power athletes. High school athletes have been reported
to have similar prevalence of use of creatine [95–97, 102].
In 2014, the NCAA reported that creatine was among the
most popular dietary supplements taken by their male
athletes (e.g., baseball - 28.1%, basketball - 14.6%,
football - 27.5%, golf - 13.0%, ice hockey - 29.4%,
lacrosse - 25.3%, soccer 11.1%, swimming - 19.2%,
tennis - 12.9%, track and field - 16.1%, wrestling - 28.5%)
3.8% in various sports . Comparatively, these NCAA
athletes reported relatively high alcohol (83%), tobacco
(10–16%), and marijuana (22%) use along with minimal
androgenic anabolic steroid use (0.4%). As will be noted
below, no study has reported any adverse or ergolytic
effect of short- or long-term creatine supplementation
while numerous studies have reported performance
and/or health benefits in athletes and individuals with
various diseases. Therefore, the prevalence of alcohol,
tobacco and drug use among NCAA athletes would
seemingly be a much greater health concern than ath-
letes taking creatine.
Other applications in sport and training
Recent research demonstrates a number of other appli-
cations of creatine supplementation that may benefit
athletes involved in intense training and individuals who
want to enhance training adaptations. For example, use
of creatine during training may enhance recovery, re-
duce the risk of injury and/or help individuals recover
from injuries at a faster rate. The following describes
some applications of creatine in addition to serving as
an ergogenic aid.
Creatine supplementation can help athletes recover from
intense training. For example, Green and coworkers 
reported that co-ingesting creatine (5 g) with large
amounts of glucose (95 g) enhanced creatine and carbo-
hydrate storage in muscle. Additionally, Steenge et al.
 reported that co-ingesting creatine (5 g) with 47–
97 g of carbohydrate and 50 g of protein enhanced creat-
ine retention. Nelson and colleagues  reported that
creatine loading prior to performing an exhaustive exer-
cise bout and glycogen loading promoted greater glyco-
gen restoration than just carbohydrate loading alone.
Since glycogen replenishment is important to promoting
recovery and preventing overtraining during intensified
training periods , creatine supplementation may help
athletes who deplete large amounts of glycogen during
training and/or performance to maintain optimal glyco-
Evidence also suggests that creatine supplementation
may reduce muscle damage and/or enhance recovery
from intense exercise. For example, Cooke and associ-
ates  evaluated the effects of creatine supplementa-
tion on muscle force recovery and muscle damage
following intense exercise. They reported that partici-
pants supplemented with creatine had significantly
greater isokinetic (+10%) and isometric (+21%) knee ex-
tension strength during recovery from exercise-induced
muscle damage. Additionally, plasma CK levels were sig-
nificantly lower (−84%) after 2, 3, 4, and 7 days of recov-
ery in the creatine supplemented group compared to
controls. The authors concluded that creatine improved
the rate of recovery of knee extensor muscle function
after injury. Santos and coworkers  evaluated the
effects of creatine loading in experienced marathon run-
ners prior to performing a 30 km race on inflammatory
markers and muscle soreness. The researchers reported
that creatine loading attenuated the changes in CK
(−19%), prostaglandin E2 (−61%), and tumor necrosis
factor (TNF) alpha (−34%) and abolished the increase in
lactate dehydrogenase (LDH) compared to controls.
Similar findings were reported by Demince et al. 
who reported that creatine supplementation inhibited
the increase of inflammatory markers (TNF-alpha and
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 6 of 18
C-reactive protein) in response to intermittent anaerobic
sprint exercise. Finally, Volek and colleagues  eval-
uated the effects of creatine supplementation (0.3 g/
kg/d) for 4 weeks during an intensified overreaching
period followed by a 2 weeks taper. The researchers
found that creatine supplementation was effective in
maintaining muscular performance during the initial
phase of high-volume resistance training overreaching
that otherwise results in small performance decre-
ments. These findings suggest that creatine supple-
mentation can help athletes tolerate heavy increases
in training volume. Therefore, there is strong evi-
dence that creatine supplementation can help athletes
enhance glycogen loading; experience less inflamma-
tion and/or muscle enzyme efflux following intense
exercise; and tolerate high volumes of training and/or
overreaching to a greater degree thereby promoting
Several studies have reported that creatine supplementa-
tion during training and/or competition either has no ef-
fect or reduces the incidence of musculoskeletal injury,
dehydration, and/or muscle cramping. For example, sev-
eral initial studies on creatine supplementation provided
15–25 g/day of creatine monohydrate for 4 –12 weeks
in athletes engaged in heavy training with no reported
side effects [67, 77, 108–110]. Kreider and colleagues
 reported that American collegiate football players
ingesting 20 or 25 g/day of creatine monohydrate with a
carbohydrate/protein supplement for 12 weeks during
off season conditioning and spring football practice ex-
perienced greater gains in strength and muscle mass
with no evidence of any adverse side effects. Addition-
ally, in a study specifically designed to assess the safety
of creatine supplementation, American collegiate foot-
ball players ingesting about 16 g/day of creatine for 5
days and 5–10 g/day for 21 months had no clinically sig-
nificant differences among creatine users and controls in
markers of renal function, muscle and liver enzymes,
markers of catabolism, electrolytes, blood lipids, red cell
status, lymphocytes, urine volume, clinical urinalysis, or
urine specific gravity . Meanwhile, creatine users
experienced less incidence of cramping, heat illness/de-
hydration, muscle tightness, muscle strains/pulls, non-
contact injuries, and total injuries/missed practices than
those not taking creatine .
Similar findings were reported by Greenwood and co-
workers  who examined injury rates during a 4
months American collegiate football season among cre-
atine users (0.3 g/kg/day for 5 days, 0.03 g/kg/day for 4
months) and non-users. The researchers reported that
creatine users experienced significantly less incidence of
muscle cramping, heat illness/dehydration, muscle
tightness, muscle strains, and total injuries compared to
athletes who did not supplement their diet with creatine.
Likewise, Cancela and associates  reported that cre-
atine supplementation (15 g/day x 7-d, 3 g/day x 49-d)
during soccer training promoted weight gain but that
those taking creating had no negative effects on blood
and urinary clinical health markers. Finally, Schroder et
al.  evaluated the effects of ingesting creatine (5 g/
day) for three competitive seasons in professional bas-
ketball players. The researchers found that long-term
low-dose creatine monohydrate supplementation did not
promote clinically significant changes in health markers
or side effects. Thus, contrary to unsubstantiated re-
ports, the peer-reviewed literature demonstrates that
there is no evidence that: 1) creatine supplementation in-
creases the anecdotally reported incidence of musculo-
skeletal injuries, dehydration, muscle cramping,
gastrointestinal upset, renal dysfunction, etc.; or that 2)
long-term creatine supplementation results in any clinic-
ally significant side effects among athletes during train-
ing or competition for up to 3 years. If anything,
evidence reveals that athletes who take creatine during
training and competition experience a lower incidence
of injuries compared to athletes who do not supplement
their diet with creatine.
Enhanced tolerance to exercise in the heat
Like carbohydrate, creatine monohydrate has osmotic
properties that help retain a small amount of water. For
example, initial studies reported that creatine loading
promoted a short-term fluid retention (e.g., about 0.5 –
1.0 L) that was generally proportional to the acute
weight gain observed [22, 46]. For this reason, there was
interest in determining if creatine supplementation may
help hyper-hydrate an athlete and/or improve exercise
tolerance when exercising in the heat [76, 115–126]. For
example, Volek and colleagues  evaluated the effects
of creatine supplementation (0.3 g/kg/day for 7 days) on
acute cardiovascular, renal, temperature, and fluid-
regulatory hormonal responses to exercise for 35 min in
the heat. The researchers reported that creatine supple-
mentation augmented repeated sprint cycle performance
in the heat without altering thermoregulatory responses.
Kilduff and associates  evaluated the effects of cre-
atine supplementation (20 g/day for 7 days) prior to per-
forming exercise to exhaustion at 63% of peak oxygen
uptake in the heat (30.3 °C). The researchers reported
that creatine supplementation increased intracellular
water and reduced thermoregulatory and cardiovascu-
lar responses to prolonged exercise (e.g., heart rate,
rectal temperature, sweat rate) thereby promoting
hyper-hydration and a more efficient thermoregulatory
response during prolonged exercise in the heat. Wat-
son and colleagues  reported that short-term
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 7 of 18
creatine supplementation (21.6 g/day for 7 days) did
not increase the incidence of symptoms or comprom-
ise hydration status or thermoregulation in dehy-
drated (−2%), trained men exercising in the heat.
Similar findings were observed by several other
groups [118, 119, 127, 128] leading researchers to add
creatine to glycerol as a highly effective hyper-
hydrating strategy to help athletes better tolerate ex-
ercise in the heat [116, 120–122, 125, 126]. These
findings provide strong evidence that creatine supplemen-
tation (with or without glycerol) may serve as an effective
nutritional hyper-hydration strategy for athletes engaged
in intense exercise in hot and humid environments
thereby reducing risk to heat related-illness [5, 129].
Enhanced rehabilitation from injury
Since creatine supplementation has been reported to
promote gains in muscle mass and improved strength,
there has been interest in examining the effects of creat-
ine supplementation on muscle atrophy rates as a result
of limb immobilization and/or during rehabilitation
. For example, Hespel and coworkers  exam-
ined the effects of creatine supplementation (20 g/day
down to 5 g/day) on atrophy rates and rehabilitation
outcomes in individuals who had their right leg casted
for 2 weeks. During the 10 week rehabilitation phase,
participants performed three sessions a week of knee ex-
tension rehabilitation. The researchers reported that in-
dividuals in the creatine group experienced greater
changes in the cross-sectional area of muscle fiber
(+10%) and peak strength (+25%) during the rehabilita-
tion period. These changes were associated with greater
changes in myogenic regulating factor 4 (MRF4) and
myogenic protein expression. In a companion paper to
this study, Op’t Eijnde et al.  reported that creatine
supplementation offset the decline in muscle GLUT4
protein content that occurs during immobilization and
increased GLUT4 protein content during subsequent re-
habilitation training in healthy subjects. Collectively,
these findings suggest that creatine supplementation
lessened the amount of muscle atrophy and detrimental
effects on muscle associated with immobilization while
promoting greater gains in strength during rehabilita-
tion. Similarly, Jacobs and associates  examined the
effects of creatine supplementation (20 g/d for 7 days)
on upper extremity work capacity in individuals with
cervical-level spinal cord injury (SCI). Results revealed
that peak oxygen uptake and ventilatory anaerobic
threshold were increased following creatine supplemen-
tation. Conversely, Tyler et al.  reported that creat-
ine supplementation (20 g/day for 7 days, and 5 g/day
thereafter) did not significantly affect strength or func-
tional capacity in patients recovering from anterior cru-
ciate ligament (ACL) surgery. Moreover, Perret and
colleagues  reported that creatine supplementation
(20 g/day for 6 days) did not enhance 800 m wheelchair
performance in trained SCI wheelchair athletes. While
not all studies show benefit, there is evidence that creat-
ine supplementation may help lessen muscle atrophy fol-
lowing immobilization and promote recovery during
exercise-related rehabilitation in some populations.
Thus, creatine supplementation may help athletes and
individuals with clinical conditions recover from injuries.
Brain and spinal cord neuroprotection
The risk of concussions and/or SCI in athletes involved
in contact sports has become an international concern
among sports organizations and the public. It has been
known for a long time that creatine supplementation
possesses neuroprotective benefits [29, 38, 40, 136]. For
this reason, a number of studies have examined the ef-
fects of creatine supplementation on traumatic brain in-
jury (TBI), cerebral ischemia, and SCI. For example,
Sullivan et al.  examined the effects of 5 days of
creatine administration prior to a controlled TBI in rats
and mice. The researchers found that creatine monohy-
drate ameliorated the extent of cortical damage by 36 to
50%. The protection appeared to be related to creatine-
induced maintenance of neuronal mitochondrial bio-
energetics. Therefore, the researchers concluded that
creatine supplementation may be useful as a neuropro-
tective agent against acute and chronic neurodegenera-
tive processes. In a similar study, Haussmann and
associates  investigated the effects of rats fed creat-
ine (5 g/100 g dry food) before and after a moderate
SCI. The researchers reported that creatine ingestion im-
proved locomotor function tests and reduced the size of
scar tissue after the SCI. The authors suggested that pre-
treatment of patients with creatine may provide neuro-
protection in patients undergoing spinal surgery who are
at risk to SCI. Similarly, Prass and colleagues  re-
ported findings that creatine administration reduced
brain infarct size following an ischemic event by 40%.
Adcock et al.  reported that neonatal rats fed 3 g/
kg of creatine for 3 days observed a significant increase
in the ratio of brain PCr to Pi and a 25% reduction in
the volume of edemic brain tissue following cerebral
hypoxic ischemia. The authors concluded that creatine
supplementation appears to improve brain bioenergetics
thereby helping minimize the impact of brain ischemia.
Similarly, Zhu and colleagues  reported that oral
creatine administration resulted in a marked reduction
in ischemic brain infarction size, neuronal cell death,
and provided neuroprotection after cerebral ischemia in
mice. The authors suggested that given the safety record
of creatine, creatine might be considered as a novel
therapeutic agent for inhibition of ischemic brain injury
in humans. Allah et al.  reported that creatine
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 8 of 18
monohydrate supplementation for 10 weeks reduced the
infarction size and improved learning/memory following
neonatal hypoxia ischemia encephalopathy in female
mice. The authors concluded that creatine supplementa-
tion has the potential to improve the neuro-function fol-
lowing neonatal brain damage. Finally, Rabchevsky and
associates  examined the efficacy of creatine-
supplemented diets on hind limb functional recovery
and tissue sparing in adult rats. Rats were fed a control
diet or 2% creatine-supplemented chow for 4–5 weeks
prior to and following SCI. Results revealed that creatine
feeding significantly reduced loss of gray matter after
SCI. These findings provide strong evidence that creat-
ine supplementation may limit damage from concus-
sions, TBI, and/or SCI [33, 144].
Potential medical uses of creatine
Given the role of creatine in metabolism, performance,
and training adaptations; a number of researchers have
been investigating the potential therapeutic benefits of
creatine supplementation in various clinical populations.
The following highlights some of these applications.
Creatine synthesis deficiencies
Creatine deficiency syndromes are a group of inborn er-
rors (e.g., AGAT deficiency, GAMT deficiency, and
CRTR deficiency) that reduce or eliminate the ability to
endogenously synthesize or effect transcellular creatine
transport . Individuals with creatine synthesis defi-
ciencies have low levels of creatine and PCr in the
muscle and the brain. As a result, they often have clin-
ical manifestations of muscle myopathies, gyrate atrophy,
movement disorders, speech delay, autism, mental
retardation, epilepsy, and/or developmental problems
[13, 17, 145]. For this reason, a number of studies have in-
vestigated the use of relatively high doses of creatine mono-
hydrate supplementation (e.g., 0.3 –0.8 g/kg/day equivalent
to 21 –56g/dayofcreatinefora70kgperson,or1–2.7
times greater than the adult loading dose) throughout the
lifespan as a means of treating children and adults with cre-
atine synthesis deficiencies [13, 17, 145–149]. These studies
generally show some improvement in clinical outcomes
particularly for AGAT and GAMT with less consistent ef-
fects on CRTR deficiencies .
For example, Battini et al.  reported that a patient
diagnosed at birth with AGAT deficiency who was
treated with creatine supplementation beginning at 4
months of age experienced normal psychomotor devel-
opment at 18 months compared to siblings who did not
have the deficiency. Stockler-Ipsiroglu and coworkers
 evaluated the effects of creatine monohydrate sup-
plementation (0.3 –0.8 g/kg/day) in 48 children with
GMAT deficiency with clinical manifestations of global
developmental delay/intellectual disability (DD/ID) with
speech/language delay and behavioral problems (n= 44),
epilepsy (n= 35), or movement disorder (n= 13). The
median age at treatment was 25.5 months, 39 months,
and 11 years in patients with mild, moderate, and severe
DD/ID, respectively. The researchers found that creatine
supplementation increased brain creatine levels and im-
proved or stabilized clinical symptoms. Moreover, four
patients treated younger than 9 months had normal or
almost normal developmental outcomes. Long-term cre-
atine supplementation has also been used to treat pa-
tients with creatine deficiency-related gyrate atrophy
[152–156]. These findings and others provide promise
that high-dose creatine monohydrate supplementation
may be an effective adjunctive therapy for children and
adults with creatine synthesis deficiencies [18, 145, 157–
159]. Additionally, these reports provide strong evidence
regarding the long-term safety and tolerability of high-
dose creatine supplementation in pediatric populations
with creatine synthesis deficiencies, including infants less
than 1 year of age .
A number of studies have investigated the short and long-
term therapeutic benefit of creatine supplementation in
children and adults with various neuromuscular diseases
like muscular dystrophies [160–165], Huntington’s disease
[23, 166–171]; Parkinson disease [23, 40, 166, 172–174];
mitochondria-related diseases [29, 175–177]; and,
amyotrophic lateral sclerosis or Lou Gehrig’sDisease
[166, 178–184]. These studies have provided some
evidence that creatine supplementation may improve
exercise capacity and/or clinical outcomes in these
patient populations. However, Bender and colleagues
 recently reported results of several large clinical
trials evaluating the effects of creatine supplementa-
tion in patients with Parkinson’s disease (PD),
Huntington’s disease (HD), and amyotrophic lateral
sclerosis (ALS). A total of 1,687 patients took an
patient years. Results revealed no clinical benefit on
patient outcomes in patients with PD or ALS. How-
ever, there was some evidence that creatine supple-
mentation slowed down progression of brain atrophy
in patients with HD (although clinical markers were
unaffected). Whether creatine supplementation may
have a role in mediating other clinical markers in
these patient populations and/or whether individual
patients may respond more positively to creatine sup-
plementation than others, remain to be determined.
Nevertheless, these studies show that creatine supple-
mentation has been used to treat children and adults
with neurodegenerative conditions and is apparently
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 9 of 18
safe and well-tolerated when taking up to 30 g/day
for 5 years in these populations.
Ischemic heart disease
Creatine and phosphocreatine play an important role in
maintaining myocardial bioenergetics during ischemic
events . For this reason, there has been interest in
assessing the role of creatine or phosphocreatine in re-
ducing arrhythmias and/or improving heart function
during ischemia [185–194]. In a recent review, Bales-
trino and colleagues  concluded that phosphocrea-
tine administration, primarily as an addition to
cardioplegic solutions, has been used to treat myocardial
ischemia and prevent ischemia-induced arrhythmia and
improve cardiac function with some success. They sug-
gested that creatine supplementation may protect the
heart during an ischemic event. Thus, prophylactic cre-
atine supplementation may be beneficial for patients at
risk for myocardial ischemia and/or stroke.
A growing collection of evidence supports that creatine
supplementation may improve health status as individ-
uals age [41, 43–45, 195]. In this regard, creatine supple-
mentation has been reported to help lower cholesterol
and triglyceride levels [67, 196]; reduce fat accumulation
in the liver ; reduce homocysteine levels ;
serve as an antioxidant [199–202]; enhance glycemic
control [132, 203–205]; slow tumor growth in some
types of cancers [32, 198, 206, 207]; increase strength
and/or muscle mass [37, 41, 44, 45, 82, 208–212];
minimize bone loss [211, 212]; improve functional cap-
acity in patients with knee osteoarthritis  and fibro-
myalgia ; positively influence cognitive function
[43, 83, 195]; and in some instances, serve as an anti-
For example, Gualano and associates supplemented
patients with type II diabetes with a placebo or creatine
(5 g/day) for 12 weeks during training. Creatine supple-
mentation significantly decreased HbA1c and glycemic
response to standardized meal as well as increased
GLUT-4 translocation. These findings suggest that creat-
ine supplementation combined with an exercise program
improves glycemic control and glucose disposal in type
2 diabetic patients. Candow and others  reported
that low-dose creatine (0.1 g/kg/day) combined with
protein supplementation (0.3 g/kg/day) increased lean
tissue mass and upper body strength while decreasing
markers of muscle protein degradation and bone resorp-
tion in older men (59–77 years). Similarly, Chilibeck et
al.  reported that 12 months of creatine supplemen-
tation (0.1 g/kg/day) during resistance training increased
strength and preserved femoral neck bone mineral dens-
ity and increased femoral shaft subperiosteal width in
postmenopausal women. A recent meta-analysis  of
357 elderly individuals (64 years) participating in an aver-
age of 12.6 weeks of resistance training found that partici-
pants supplementing their diet with creatine experienced
greater gains in muscle mass, strength, and functional
capacity. These findings were corroborated in a meta-
analysis of 405 elderly participants (64 years) who experi-
enced greater gains in muscle mass and upper body
strength with creatine supplementation during resistance-
training compared to training alone . These findings
suggest that creatine supplementation can help prevent
sarcopenia and bone loss in older individuals.
Finally, a number of studies have shown that creatine
supplementation can increase brain creatine content
generally by 5 –15% [218–220]. Moreover, creatine sup-
plementation can reduce mental fatigue  and/or im-
prove cognitive function [83, 222–225]. For example,
Watanabe et al.  reported that creatine supplemen-
tation (8 g/day for 5 days) reduced mental fatigue when
subjects repeatedly performed a simple mathematical
calculation as well as increased oxygen utilization in the
brain. Rae and colleagues  reported that creatine
supplementation (5 g/day for 6 weeks) significantly
improved working memory and intelligence tests re-
quiring speed of processing. McMorris and co-
workers  found that creatine supplementation
(20 g/day for 7 days) after sleep deprivation demon-
strated significantly less decrement in performance in
random movement generation, choice reaction time,
balance and mood state suggesting that creatine im-
proves cognitive function in response to sleep
deprivation. This research group also examined the
effects of creatine supplementation (20 g/day for 7
days) on cognitive function in elderly participants
and found that creatine supplementation significantly
improved performance on random number gener-
ation, forward spatial recall, and long-term memory
tasks. Ling and associates  reported that creat-
ine supplementation (5 g/day for 15 days) improved
cognition on some tasks. Since creatine uptake by
the brain is slow and limited, current research is in-
vestigating whether dietary supplementation of creat-
ine precursors like GAA may promote greater
increases in brain creatine [226, 227]. One recent
study suggested that GAA supplementation (3 g/day)
increased brain creatine content to a greater degree
than creatine monohydrate .
Since creatine supplementation has been shown to
improve brain and heart bioenergetics during ische-
mic conditions and possess neuroprotective proper-
ties, there has been recent interest in use of creatine
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 10 of 18
during pregnancy to promote neural development and
reduce complications resulting from birth asphyxia
[228–237]. The rationale for creatine supplementation
during pregnancy is that the fetus relies upon placental
transfer of maternal creatine until late in pregnancy and
significant changes in creatine synthesis and excretion
occur as pregnancy progresses [230, 232]. Consequently,
there is an increased demand for and utilization of
creatine during pregnancy. Maternal creatine supple-
mentation has been reported to improve neonatal sur-
vival and organ function following birth asphyxia in
animals [228, 229, 231, 233–235, 237]. Human studies
show changes in the maternal urine and plasma creat-
ine levels across pregnancy and association to mater-
nal diet [230, 232]. Consequently, it has been
postulated that there may be benefit to creatine sup-
plementation during pregnancy on fetal growth, devel-
opment, and health [230, 232]. This area of research
may have broad implications for fetal and child devel-
opment and health.
Since creatine monohydrate became a popular dietary sup-
plement in the early 1990s, over 1,000 studies have been
conducted and billions of servings of creatine have been
ingested. The only consistently reported side effect from
creatine supplementation that has been described in the lit-
erature has been weight gain [5, 22, 46, 78, 91, 92, 112].
Available short and long-term studies in healthy and dis-
eased populations, from infants to the elderly, at dosages
ranging from 0.3 to 0.8 g/kg/day for up to 5 years have con-
sistently shown that creatine supplementation poses no ad-
verse health risks and may provide a number of health and
performance benefits. Additionally, assessments of adverse
event reports related to dietary supplementation, including
in pediatric populations, have revealed that creatine was
rarely mentioned and was not associated with any signifi-
cant number or any consistent pattern of adverse events
[238–240]. Unsubstantiated anecdotal claims described in
the literature without rigorous, systematic causality assess-
ments have been refuted in numerous well-controlled clin-
ical studies showing that creatine supplementation does not
increase the incidence of musculoskeletal injuries [22, 111,
112, 241], dehydration [111, 112, 117, 122, 127–129, 242],
muscle cramping [76, 106, 111, 112, 117], or gastrointes-
tinal upset [22, 111, 112, 241]. Nor has the literature pro-
vided any support that creatine promotes renal dysfunction
[22, 51, 85, 114, 156, 172, 243–248] or has long-term detri-
mental effects [22, 23, 53, 155, 172]. Rather, as noted above,
creatine monohydrate supplementation has been found to
reduce the incidence of many of these anecdotally reported
With regard to the question of whether creatine has
effect on renal function, a few case studies [249–252] re-
ported that individuals purportedly taking creatine with
or without other supplements presented with high cre-
atinine levels and/or renal dysfunction [249–251]. Add-
itionally, one study suggested that feeding rats with renal
cystic disease 2 g/kg/d of creatine for 1 week (equivalent
to 140 g/day for a 70 kg individual) and 0.4 g/kg/d
(equivalent to 28 g/day for a 70 kg individual) for 4
weeks exacerbated disease progression. These reports
prompted some concern that creatine supplementation
may impair renal function [253–256] and prompted a
number of researchers to examine the impact of creatine
supplementation on renal function [22, 51, 85, 114, 156,
172, 243–248, 257–259]. For example, Ferreira and asso-
ciates  reported that creatine feeding (2 g/kg/d for
10 weeks equivalent to 140 g/kg/d in a 70 kg person)
had no effects on glomerular filtration rate and renal
plasma flow in Wistar rats. Likewise, Baracho and col-
leagues  reported that Wistar rats fed 0, 0.5, 1, or
2 g/kg/d of creatine did not result in renal and/or hep-
atic toxicity. Poortmans and coworkers reported that
ingesting 20 g/day of creatine for 5 days , and up to
10 g/day from 10 months to 5 years  had no effect
on creatine clearance, glomerular filtration rate, tubular
resorption, or glomerular membrane permeability com-
pared to controls. Kreider et al.  reported that creat-
ine supplementation (5–10 g/day for 21 months) had no
significant effects on creatinine or creatinine clearance
in American football players. Gualono and associates
 reported that 12 weeks of creatine supplementa-
tion had no effects on kidney function in type 2 diabetic
patients. Finally, creatine supplement has been used as a
means of reducing homocysteine levels and/or improv-
ing patient outcomes in patients with renal disease
[263–265] as well as ameliorating birth asphyxia related
renal dysfunction in mice . Moreover, long-term,
high dose ingestion of creatine (up to 30 g/d for up
to 5 years) in patient populations has not been asso-
ciated with an increased incidence of renal dysfunc-
tion [23, 155, 156, 172]. While some have suggested
that individuals with pre-existing renal disease consult
with their physician prior to creatine supplementation
in an abundance of caution, these studies and others
have led researchers to conclude that there is no
compelling evidence that creatine supplementation
negatively affects renal function in healthy or clinical
populations [5, 6, 22, 53, 259, 266, 267].
Performance-related studies in adolescents, younger
individuals, and older populations have consistently re-
ported ergogenic benefits with no clinically significant
side effects [5, 6, 22, 23, 53, 113, 129, 244, 245, 268].
The breadth and repetition of these findings provide
compelling evidence that creatine monohydrate is well-
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 11 of 18
tolerated and is safe to consume in healthy untrained
and trained individuals regardless of age. Moreover, as
noted above, the number of potential medical uses of
creatine supplementation that can improve health and
well-being as one ages and/or may provide therapeutic
benefit in clinical populations ranging from infants to
senior adults has continued to grow without identifying
significant risks or adverse events even in these diseased
or compromised special populations. It is no wonder
that Wallimann and colleagues  recommended that
individuals should consume 3 g/day of creatine through-
out the lifespan to promote general health.
Some critics of creatine supplementation have pointed
to warnings listed on some product labels that individ-
uals younger than 18 years of age should not take creat-
ine as evidence that creatine supplementation is unsafe
in younger populations. It’s important to understand that
this is a legal precaution and that there is no scientific
evidence that children and/or adolescents should not
take creatine. As noted above, a number of short- and
long-term studies using relatively high doses of creatine
have been conducted in infants, toddlers and adolescents
with some health and/or ergogenic benefit observed.
These studies provide no evidence that use of creatine at
recommended doses pose a health risk to individuals less
than 18 years of age. Creatine supplementation may, how-
ever, improve training adaptations and/or reduce risk to
injury, including in younger athletes. For this reason, it is
our view that creatine supplementation is an acceptable
nutritional strategy for younger athletes who: a.) are in-
volved in serious/competitive supervised training; b.) are
consuming a well-balanced and performance enhancing
diet; c.) are knowledgeable about appropriate use of creat-
ine; and d.) do not exceed recommended dosages.
Position of the internationals society of sports
After reviewing the scientific and medical literature in
this area, the International Society of Sports Nutrition
concludes the following in terms of creatine supplemen-
tation as the official Position of the Society:
1. Creatine monohydrate is the most effective
ergogenic nutritional supplement currently available
to athletes with the intent of increasing high-
intensity exercise capacity and lean body mass dur-
2. Creatine monohydrate supplementation is not only
safe, but has been reported to have a number of
therapeutic benefits in healthy and diseased
populations ranging from infants to the elderly.
There is no compelling scientific evidence that the
short- or long-term use of creatine monohydrate (up
to 30 g/day for 5 years) has any detrimental effects
on otherwise healthy individuals or among clinical
populations who may benefit from creatine
3. If proper precautions and supervision are provided,
creatine monohydrate supplementation in children
and adolescent athletes is acceptable and may
provide a nutritional alternative with a favorable
safety profile to potentially dangerous anabolic
androgenic drugs. However, we recommend that
creatine supplementation only be considered for use
by younger athletes who: a.) are involved in serious/
competitive supervised training; b.) are consuming a
well-balanced and performance enhancing diet; c.)
are knowledgeable about appropriate use of creatine;
and d.) do not exceed recommended dosages.
4. Label advisories on creatine products that caution
against usage by those under 18 years old, while
perhaps intended to insulate their manufacturers
from legal liability, are likely unnecessary given the
science supporting creatine’s safety, including in
children and adolescents.
5. At present, creatine monohydrate is the most
extensively studied and clinically effective form of
creatine for use in nutritional supplements in terms
of muscle uptake and ability to increase high-
intensity exercise capacity.
6. The addition of carbohydrate or carbohydrate and
protein to a creatine supplement appears to increase
muscular uptake of creatine, although the effect on
performance measures may not be greater than
using creatine monohydrate alone.
7. The quickest method of increasing muscle creatine
stores may be to consume ~0.3 g/kg/day of creatine
monohydrate for 5–7-days followed by 3–5 g/day
thereafter to maintain elevated stores. Initially,
ingesting smaller amounts of creatine monohydrate
(e.g., 3–5 g/day) will increase muscle creatine stores
over a 3–4 week period, however, the initial
performance effects of this method of
supplementation are less supported.
8. Clinical populations have been supplemented with
high levels of creatine monohydrate (0.3 –0.8 g/kg/
day equivalent to 21–56 g/day for a 70 kg individual)
for years with no clinically significant or serious
9. Further research is warranted to examine the
potential medical benefits of creatine monohydrate
and precursors like guanidinoacetic acid on sport,
health and medicine.
Creatine monohydrate remains one of the few nutritional
supplements for which research has consistently shown
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 12 of 18
has ergogenic benefits. Additionally, a number of potential
health benefits have been reported from creatine supple-
mentation. Comments and public policy related to
creatine supplementation should be based on careful as-
sessment of the scientific evidence from well-controlled
clinical trials; not unsubstantiated anecdotal reports,
misinformation published on the Internet, and/or poorly
designed surveys that only perpetuate myths about
creatine supplementation. Given all the known benefits
and favorable safety profile of creatine supplementation
reported in the scientific and medical literature, it is the
view of ISSN that government legislatures and sport orga-
nizations who restrict and/or discourage use of creatine
may be placing athletes at greater risk—particularly in
contact sports that have risk of head trauma and/or
neurological injury thereby opening themselves up to legal
liability. This includes children and adolescent athletes
engaged in sport events that place them at risk for head
and/or spinal cord injury.
We would like to thank all of the participants and researchers who
contributed to the research studies and reviews described in this position
stand. Your dedication to conducing groundbreaking research has improved
the health and well-being of countless athletes and patients.
Prepared as a Position Stand on behalf of the International Society of Sport
Nutrition with approval of Editors-In-Chief, Founders, and Research
Support to prepare this manuscript was provided by the Council for
Availability of data and materials
RBK prepared the manuscript. Remaining coauthors reviewed, edited, and
approved the final manuscript. The manuscript was then approved by the
Research Committee and Editors-In Chief to represent the official position of
the International Society of Sports Nutrition.
RBK is a co-founder of the International Society of Sports Nutrition (ISSN) and
has received externally-funded grants from industry to conduct research on
creatine, serves as a scientific and legal consultant, and is a university approved
scientific advisor for Nutrabolt. He prepared this position stand update at the
request of the Council for Responsible Nutrition and ISSN. DSK is a co-founder
of the ISSN who works for a contract research organization (QPS). QPS has
received research grants from companies who sell creatine. DSK sits in an
advisory board (Post Holdings) to Dymatize that sells creatine. DSK declares no
other conflicts of interest. JA is the CEO and co-founder of the ISSN; has
consulted in the past for various sports nutrition brands. TNZ has received
grants and contracts to conduct research on dietary supplements; has
served as a paid consultant for industry; has received honoraria for
speaking at conferences and writing lay articles about sports nutrition
ingredients; receives royalties from the sale of several sports nutrition
products; and has served as an expert witness on behalf of the plaintiff
and defense in cases involving dietary supplements. TNZ is also co-inventor on
multiple patent applications within the field of dietary supplements, applied
nutrition and bioactive compounds. RW is the Chief Science Officer for Post
Active Nutrition. ALA is CEO of Vitargo Global Sciences, Inc., a company that
markets and sells a high insulinemic, starch-based carbohydrate. HLL has
received research grants from companies who sell creatine and do business in
the dietary supplement, natural products and medical foods industry. HLL is co-
founder of Supplement Safety Solutions, LLC, serving as an independent
consultant for regulatory compliance, safety surveillance and Nutravigilance to
companies who sell creatine. Dr. Lopez is also co-inventor on multiple patent
applications within the field of dietary supplements, applied nutrition
and bioactive compounds. Remaining investigators have no competing
interests to declare. The comments and positions taken in this paper do
not constitute an endorsement by institution’s the authors are affiliated.
Consent for publication
Ethics approval and consent to participate
This paper was reviewed by the International Society of Sports Nutrition
Research Committee and represents the official position of the Society.
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Exercise & Sport Nutrition Lab, Human Clinical Research Facility, Department
of Health & Kinesiology, Texas A&M University, College Station, TX
Nutrition Research Unit, QPS, 6141 Sunset Drive Suite 301,
Miami, FL 33143, USA.
Department of Health and Human Performance,
Nova Southeastern University, Davie, FL 33328, USA.
The Center for Applied
Health Sciences, 4302 Allen Road, STE 120, Stow, OH 44224, USA.
Active Nutrition, 111 Leslie St, Dallas, TX 75208, USA.
McCloskey & Barry, PLLC, 138 Mineola Blvd., Mineola, NY 11501, USA.
of Kinesiology and Health Studies, University of Regina, Regina, SK S4S 0A2,
High Performance Nutrition, LLC, Mercer Island, WA 98040, USA.
Vitargo Global Sciences, Inc., Dana Point, CA 92629, USA.
Safety Solutions, LLC, Bedford, MA 01730, USA.
Received: 27 April 2017 Accepted: 30 May 2017
1. Bertin M, et al. Origin of the genes for the isoforms of creatine kinase.
2. Suzuki T, et al. Evolution and divergence of the genes for cytoplasmic,
mitochondrial, and flagellar creatine kinases. J Mol Evol. 2004;59(2):218–26.
3. Sahlin K, Harris RC. The creatine kinase reaction: a simple reaction with
functional complexity. Amino Acids. 2011;40(5):1363–7.
4. Harris R. Creatine in health, medicine and sport: an introduction to a
meeting held at Downing College, University of Cambridge, July 2010.
Amino Acids. 2011;40(5):1267–70.
5. Buford TW, et al. International Society of Sports Nutrition position stand:
creatine supplementation and exercise. J Int Soc Sports Nutr. 2007;4:6.
6. Kreider RB, Jung YP. Creatine supplementation in exercise, sport, and
medicine. J Exerc Nutr Biochem. 2011;15(2):53–69.
7. Hultman E, et al. Muscle creatine loading in men. J Appl Physiol (1985).
8. Green AL, et al. Carbohydrate ingestion augments skeletal muscle creatine
accumulation during creatine supplementation in humans. Am J Physiol.
1996;271(5 Pt 1):E821–6.
9. Balsom PD, Soderlund K, Ekblom B. Creatine in humans with special
reference to creatine supplementation. Sports Med. 1994;18(4):268–80.
10. Harris RC, Soderlund K, Hultman E. Elevation of creatine in resting and
exercised muscle of normal subjects by creatine supplementation. Clin Sci (Lond).
11. Brosnan ME, Brosnan JT. The role of dietary creatine. Amino Acids. 2016;
12. Paddon-Jones D, Borsheim E, Wolfe RR. Potential ergogenic effects of
arginine and creatine supplementation. J Nutr. 2004;134(10 Suppl):2888S–94S.
13. Braissant O, et al. Creatine deficiency syndromes and the importance of
creatine synthesis in the brain. Amino Acids. 2011;40(5):1315–24.
14. Wyss M, et al. Creatine and creatine kinase in health and disease–a bright
future ahead? Subcell Biochem. 2007;46:309–34.
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 13 of 18
15. Braissant O, et al. Dissociation of AGAT, GAMT and SLC6A8 in CNS:
relevance to creatine deficiency syndromes. Neurobiol Dis. 2010;37(2):
16. Beard E, Braissant O. Synthesis and transport of creatine in the CNS:
importance for cerebral functions. J Neurochem. 2010;115(2):297–313.
17. Sykut-Cegielska J, et al. Biochemical and clinical characteristics of creatine
deficiency syndromes. Acta Biochim Pol. 2004;51(4):875–82.
18. Ganesan V, et al. Guanidinoacetate methyltransferase deficiency: new
clinical features. Pediatr Neurol. 1997;17(2):155–7.
19. Hanna-El-Daher L, Braissant O. Creatine synthesis and exchanges between
brain cells: what can be learned from human creatine deficiencies and
various experimental models? Amino Acids. 2016;48(8):1877–95.
20. Benton D, Donohoe R. The influence of creatine supplementation on the
cognitive functioning of vegetarians and omnivores. Br J Nutr. 2011;105(7):
21. Burke DG, et al. Effect of creatine and weight training on muscle creatine
and performance in vegetarians. Med Sci Sports Exerc. 2003;35(11):1946–55.
22. Kreider RB, et al. Long-term creatine supplementation does not significantly
affect clinical markers of health in athletes. Mol Cell Biochem. 2003;244(1–2):
23. Bender A, Klopstock T. Creatine for neuroprotection in neurodegenerative
disease: end of story? Amino Acids. 2016;48(8):1929–40.
24. Schlattner U, et al. Cellular compartmentation of energy metabolism:
creatine kinase microcompartments and recruitment of B-type creatine
kinase to specific subcellular sites. Amino Acids. 2016;48(8):1751–74.
25. Ydfors M, et al. Modelling in vivo creatine/phosphocreatine in vitro reveals
divergent adaptations in human muscle mitochondrial respiratory control
by ADP after acute and chronic exercise. J Physiol. 2016;594(11):3127–40.
26. Wallimann T, Schlosser T, Eppenberger HM. Function of M-line-bound
creatine kinase as intramyofibrillar ATP regenerator at the receiving end of
the phosphorylcreatine shuttle in muscle. J Biol Chem. 1984;259(8):5238–46.
27. Wallimann T, Tokarska-Schlattner M, Schlattner U. The creatine kinase
system and pleiotropic effects of creatine. Amino Acids. 2011;40(5):1271–96.
28. Wallimann T, et al. Some new aspects of creatine kinase (CK):
compartmentation, structure, function and regulation for cellular and
mitochondrial bioenergetics and physiology. Biofactors. 1998;8(3–4):229–34.
29. Tarnopolsky MA, et al. Creatine transporter and mitochondrial creatine
kinase protein content in myopathies. Muscle Nerve. 2001;24(5):682–8.
30. Santacruz L, Jacobs DO. Structural correlates of the creatine transporter
function regulation: the undiscovered country. Amino Acids. 2016;48(8):
31. Braissant O. Creatine and guanidinoacetate transport at blood–brain and
blood-cerebrospinal fluid barriers. J Inherit Metab Dis. 2012;35(4):655–64.
32. Campos-Ferraz PL, et al. Exploratory studies of the potential anti-cancer
effects of creatine. Amino Acids. 2016;48(8):1993–2001.
33. Balestrino M, et al. Potential of creatine or phosphocreatine
supplementation in cerebrovascular disease and in ischemic heart disease.
Amino Acids. 2016;48(8):1955–67.
34. Saraiva AL, et al. Creatine reduces oxidative stress markers but does not
protect against seizure susceptibility after severe traumatic brain injury.
Brain Res Bull. 2012;87(2–3):180–6.
35. Rahimi R. Creatine supplementation decreases oxidative DNA damage
and lipid peroxidation induced by a single bout of resistance exercise.
J Strength Cond Res. 2011;25(12):3448–55.
36. Riesberg LA, et al. Beyond muscles: the untapped potential of creatine.
Int Immunopharmacol. 2016;37:31–42.
37. Candow DG, Chilibeck PD, Forbes SC. Creatine supplementation and aging
musculoskeletal health. Endocrine. 2014;45(3):354–61.
38. Tarnopolsky MA. Clinical use of creatine in neuromuscular and
neurometabolic disorders. Subcell Biochem. 2007;46:183–204.
39. Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders.
Cochrane Database Syst Rev. 2011;2:CD004760.
40. Tarnopolsky MA. Potential benefits of creatine monohydrate supplementation
in the elderly. Curr Opin Clin Nutr Metab Care. 2000;3(6):497–502.
41. Candow DG, et al. Strategic creatine supplementation and resistance
training in healthy older adults. Appl Physiol Nutr Metab. 2015;40(7):689–94.
42. Moon A, et al. Creatine supplementation: can it improve quality of life in the
elderly without associated resistance training? Curr Aging Sci. 2013;6(3):251–7.
43. Rawson ES, Venezia AC. Use of creatine in the elderly and evidence for
effects on cognitive function in young and old. Amino Acids. 2011;40(5):
44. Candow DG. Sarcopenia: current theories and the potential beneficial effect
of creatine application strategies. Biogerontology. 2011;12(4):273–81.
45. Candow DG, Chilibeck PD. Potential of creatine supplementation for
improving aging bone health. J Nutr Health Aging. 2010;14(2):149–53.
46. Kreider RB. Effects of creatine supplementation on performance and
training adaptations. Mol Cell Biochem. 2003;244(1–2):89–94.
47. Casey A, et al. Creatine ingestion favorably affects performance and muscle
metabolism during maximal exercise in humans. Am J Physiol. 1996;271(1
48. Greenhaff PL, et al. Influence of oral creatine supplementation of muscle
torque during repeated bouts of maximal voluntary exercise in man.
Clin Sci (Lond). 1993;84(5):565–71.
49. Steenge GR, Simpson EJ, Greenhaff PL. Protein- and carbohydrate-induced
augmentation of whole body creatine retention in humans. J Appl Physiol
50. Greenwood M, et al. Differences in creatine retention among three
nutritional formulations of oral creatine supplements. J Exerc Physiol Online.
51. Vandenberghe K, et al. Long-term creatine intake is beneficial to muscle
performance during resistance training. J Appl Physiol (1985). 1997;83(6):
52. Kim HJ, et al. Studies on the safety of creatine supplementation. Amino
53. Jager R, et al. Analysis of the efficacy, safety, and regulatory status of novel
forms of creatine. Amino Acids. 2011;40(5):1369–83.
54. Howard AN, Harris RC. Compositions containing creatine, U.S.P. Office,
Editor. United States: United States Patent Office, United States Government;
55. Edgar G, Shiver HE. The equilibrium between creatine and creatinine, in
aqueous solution: the effect of hydrogen ion. J Am Chem Soc. 1925;47:
56. Deldicque L, et al. Kinetics of creatine ingested as a food ingredient.
Eur J Appl Physiol. 2008;102(2):133–43.
57. Persky AM, Brazeau GA, Hochhaus G. Pharmacokinetics of the dietary
supplement creatine. Clin Pharmacokinet. 2003;42(6):557–74.
58. Kreider RB, et al. Effects of serum creatine supplementation on muscle
creatine content. J Exerc Physiologyonline. 2003;6(4):24–33.
59. Spillane M, et al. The effects of creatine ethyl ester supplementation
combined with heavy resistance training on body composition, muscle
performance, and serum and muscle creatine levels. J Int Soc Sports Nutr.
60. Jagim AR, et al. A buffered form of creatine does not promote greater
changes in muscle creatine content, body composition, or training
adaptations than creatine monohydrate. J Int Soc Sports Nutr. 2012;9(1):43.
61. Galvan E, et al. Acute and chronic safety and efficacy of dose dependent
creatine nitrate supplementation and exercise performance. J Int Soc Sports Nutr.
62. Cornish SM, Chilibeck PD, Burke DG. The effect of creatine monohydrate
supplementation on sprint skating in ice-hockey players. J Sports Med Phys
63. Dawson B, Vladich T, Blanksby BA. Effects of 4 weeks of creatine
supplementation in junior swimmers on freestyle sprint and swim bench
performance. J Strength Cond Res. 2002;16(4):485–90.
64. Grindstaff PD, et al. Effects of creatine supplementation on repetitive sprint
performance and body composition in competitive swimmers. Int J Sport Nutr.
65. Juhasz I, et al. Creatine supplementation improves the anaerobic
performance of elite junior fin swimmers. Acta Physiol Hung. 2009;96(3):
66. Silva AJ, et al. Effect of creatine on swimming velocity, body composition
and hydrodynamic variables. J Sports Med Phys Fitness. 2007;47(1):58–64.
67. Kreider RB, et al. Effects of creatine supplementation on body composition,
strength, and sprint performance. Med Sci Sports Exerc. 1998;30(1):73–82.
68. Stone MH, et al. Effects of in-season (5 weeks) creatine and pyruvate
supplementation on anaerobic performance and body composition in
American football players. Int J Sport Nutr. 1999;9(2):146–65.
69. Bemben MG, et al. Creatine supplementation during resistance training in
college football athletes. Med Sci Sports Exerc. 2001;33(10):1667–73.
70. Hoffman J, et al. Effect of creatine and beta-alanine supplementation on
performance and endocrine responses in strength/power athletes.
Int J Sport Nutr Exerc Metab. 2006;16(4):430–46.
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 14 of 18
71. Chilibeck PD, Magnus C, Anderson M. Effect of in-season creatine
supplementation on body composition and performance in rugby union
football players. Appl Physiol Nutr Metab. 2007;32(6):1052–7.
72. Claudino JG, et al. Creatine monohydrate supplementation on lower-limb
muscle power in Brazilian elite soccer players. J Int Soc Sports Nutr. 2014;11:32.
73. Kerksick CM, et al. Impact of differing protein sources and a creatine
containing nutritional formula after 12 weeks of resistance training.
74. Kerksick CM, et al. The effects of creatine monohydrate supplementation
with and without D-pinitol on resistance training adaptations. J Strength
Cond Res. 2009;23(9):2673–82.
75. Volek JS, et al. Creatine supplementation enhances muscular performance
during high-intensity resistance exercise. J Am Diet Assoc. 1997;97(7):765–70.
76. Volek JS, et al. Physiological responses to short-term exercise in the heat
after creatine loading. Med Sci Sports Exerc. 2001;33(7):1101–8.
77. Volek JS, et al. The effects of creatine supplementation on muscular
performance and body composition responses to short-term resistance
training overreaching. Eur J Appl Physiol. 2004;91(5–6):628–37.
78. Kreider RB, et al. ISSN exercise & sport nutrition review: research &
recommendations. J Int Soc Sports Nutr. 2010;7:7.
79. Branch JD. Effect of creatin e supplementation on body composition
and performance: a meta-analysis. Int J Sport Nutr Exerc Metab. 2003;
80. Devries MC, Phillips SM. Creatine supplementation during resistance training
in older adults-a meta-analysis. Med Sci Sports Exerc. 2014;46(6):1194–203.
81. Lanhers C, et al. Creatine supplementation and lower limb strength
performance: a systematic review and meta-analyses. Sports Med. 2015;
82. Wiroth JB, et al. Effects of oral creatine supplementation on maximal
pedalling performance in older adults. Eur J Appl Physiol. 2001;84(6):533–9.
83. McMorris T, et al. Creatine supplementation and cognitive performance in
elderly individuals. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn.
84. Rawson ES, Clarkson PM. Acute creatine supplementation in older men.
Int J Sports Med. 2000;21(1):71–5.
85. Aguiar AF, et al. Long-term creatine supplementation improves muscular
performance during resistance training in older women. Eur J Appl Physiol.
86. Tarnopolsky MA, MacLennan DP. Creatine monohydrate supplementation
enhances high-intensity exercise performance in males and females.
Int J Sport Nutr Exerc Metab. 2000;10(4):452–63.
87. Ziegenfuss TN, et al. Effect of creatine loading on anaerobic performance
and skeletal muscle volume in NCAA division I athletes. Nutrition. 2002;
88. Ayoama R, Hiruma E, Sasaki H. Effects of creatine loading on muscular
strength and endurance of female softball players. J Sports Med Phys
89. Johannsmeyer S, et al. Effect of creatine supplementation and drop-set
resistance training in untrained aging adults. Exp Gerontol. 2016;83:112–9.
90. Ramirez-Campillo R, et al. Effects of plyometric training and creatine
supplementation on maximal-intensity exercise and endurance in female
soccer players. J Sci Med Sport. 2016;19(8):682–7.
91. Rodriguez NR, et al. Position of the American Dietetic Association, dietitians
of Canada, and the American college of sports medicine: nutrition and
athletic performance. J Am Diet Assoc. 2009;109(3):509–27.
92. Thomas DT, Erdman KA, Burke LM. Position of the academy of nutrition and
dietetics, dietitians of Canada, and the American college of sports medicine:
nutrition and athletic performance. J Acad Nutr Diet. 2016;116(3):501–28.
93. Fraczek B, et al. Prevalence of the use of effective ergogenic aids among
professional athletes. Rocz Panstw Zakl Hig. 2016;67(3):271–8.
94. Brown D, Wyon M. An international study on dietary supplementation use
in dancers. Med Probl Perform Art. 2014;29(4):229–34.
95. McGuine TA, Sullivan JC, Bernhardt DT. Creatine supplementation in high
school football players. Clin J Sport Med. 2001;11(4):247–53.
96. Mason MA, et al. Use of nutritional supplements by high school football
and volleyball players. Iowa Orthop J. 2001;21:43–8.
97. LaBotz M, Smith BW. Creatine supplement use in an NCAA division I athletic
program. Clin J Sport Med. 1999;9(3):167–9.
98. Sheppard HL, et al. Use of creatine and other supplements by members of
civilian and military health clubs: a cross-sectional survey. Int J Sport Nutr
Exerc Metab. 2000;10(3):245–59.
99. Knapik JJ, et al. Prevalence of dietary supplement use by athletes:
systematic review and meta-analysis. Sports Med. 2016;46(1):103–23.
100. Casey A, et al. Supplement use by UK-based British army soldiers in training.
Br J Nutr. 2014;112(7):1175–84.
101. Huang SH, Johnson K, Pipe AL. The use of dietary supplements and
medications by Canadian athletes at the Atlanta and Sydney olympic
games. Clin J Sport Med. 2006;16(1):27–33.
102. Scofield DE, Unruh S. Dietary supplement use among adolescent athletes in
central Nebraska and their sources of information. J Strength Cond Res.
103. NCAA National Study of Substance Use Habits of College Student-Athletes.
2014. [cited 2017 March 5, 2017]; Available from: http://www.ncaa.org/sites/
default/files/Substance%20Use%20Final%20Report_FINAL.pdf. Accessed 22
104. Nelson AG, et a l. Mus cle glycogen supercompensation is e nhanced
by prior creatine supplementation. Med Sci Sports Exerc. 2001;33(7):
105. Cooke MB, et al. Creatine supplementation enhances muscle force recovery
after eccentrically-induced muscle damage in healthy individuals. J Int Soc
Sports Nutr. 2009;6:13.
106. Santos RV, et al. The effect of creatine supplementation upon inflammatory
and muscle soreness markers after a 30 km race. Life Sci. 2004;75(16):
107. Deminice R, et al. Effects of creatine supplementation on oxidative stress
and inflammatory markers after repeated-sprint exercise in humans.
108. Kreider RB, et al. Effects of ingesting supplements designed to promote
lean tissue accretion on body composition during resistance training. Int J
Sport Nutr. 1996;6(3):234–46.
109. Kreider RB, et al. Effects of nutritional supplementation during off-season
college football training on body composition and strength. J Exerc Physiol
110. Earnest CP, et al. The effect of creatine monohydrate ingestion on
anaerobic power indices, muscular strength and body composition. Acta
Physiol Scand. 1995;153(2):207–9.
111. Greenwood M, et al. Creatine supplementation during college football
training does not increase the incidence of cramping or injury. Mol Cell
112. Greenwood M, et al. Cramping and injury incidence in collegiate football players
Are reduced by creatine supplementation. J Athl Train. 2003;38(3):216–9.
113. Cancela P, et al. Creatine supplementation does not affect clinical health
markers in football players. Br J Sports Med. 2008;42(9):731–5.
114. Schroder H, Terrados N, Tramullas A. Risk assessment of the potential side
effects of long-term creatine supplementation in team sport athletes.
Eur J Nutr. 2005;44(4):255–61.
115. Rosene JM, Whitman SA, Fogarty TD. A comparison of thermoregulation
with creatine supplementation between the sexes in a thermoneutral
environment. J Athl Train. 2004;39(1):50–5.
116. Twycross-Lewis R, et al. The effects of creatine supplementation on
thermoregulation and physical (cognitive) performance: a review and future
prospects. Amino Acids. 2016;48(8):1843–55.
117. Watson G, et al. Creatine use and exercise heat tolerance in dehydrated
men. J Athl Train. 2006;41(1):18–29.
118. Weiss BA, Powers ME. Creatine supplementation does not impair the
thermoregulatory response during a bout of exercise in the heat. J Sports
Med Phys Fitness. 2006;46(4):555–63.
119. Wright GA, Grandjean PW, Pascoe DD. The effects of creatine loading on
thermoregulation and intermittent sprint exercise performance in a hot
humid environment. J Strength Cond Res. 2007;21(3):655–60.
120. Beis LY, et al. The effects of creatine and glycerol hyperhydration on
running economy in well trained endurance runners. J Int Soc Sports Nutr.
121. Easton C, et al. The effects of a novel “fluid loading”strategy on
cardiovascular and haematological responses to orthostatic stress.
Eur J Appl Physiol. 2009;105(6):899–908.
122. Easton C, Turner S, Pitsiladis YP. Creatine and glycerol hyperhydration in
trained subjects before exercise in the heat. Int J Sport Nutr Exerc Metab.
123. Kilduff LP, et al. The effects of creatine supplementation on cardiovascular,
metabolic, and thermoregulatory responses during exercise in the heat in
endurance-trained humans. Int J Sport Nutr Exerc Metab. 2004;14(4):443–60.
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 15 of 18
124. Polyviou TP, et al. Effects of glycerol and creatine hyperhydration on
doping-relevant blood parameters. Nutrients. 2012;4(9):1171–86.
125. Polyviou TP, et al. The effects of hyperhydrating supplements containing
creatine and glucose on plasma lipids and insulin sensitivity in endurance-
trained athletes. J Amino Acids. 2015;2015:352458.
126. Polyviou TP, et al. Thermoregulatory and cardiovascular responses to
creatine, glycerol and alpha lipoic acid in trained cyclists. J Int Soc Sports
127. Lopez RM, et al. Does creatine supplementation hinder exercise heat
tolerance or hydration status? a systematic review with meta-analyses.
J Athl Train. 2009;44(2):215–23.
128. Rosene JM, et al. The effects of creatine supplementation on
thermoregulation and isokinetic muscular performance following acute
(3-day) supplementation. J Sports Med Phys Fitness. 2015;55(12):1488–96.
129. Dalbo VJ, et al. Putting to rest the myth of creatine supplementation
leading to muscle cramps and dehydration. Br J Sports Med. 2008;42(7):
130. Hespel P, Derave W. Ergogenic effects of creatine in sports and
rehabilitation. Subcell Biochem. 2007;46:245–59.
131. Hespel P, et al. Oral creatine supplementation facilitates the rehabilitation of
disuse atrophy and alters the expression of muscle myogenic factors in
humans. J Physiol. 2001;536(Pt 2):625–33.
132. Op’t Eijnde B, et al. Effect of oral creatine supplementation on human
muscle GLUT4 protein content after immobilization. Diabetes. 2001;50(1):
133. Jacobs PL, et al. Oral creatine supplementation enhances upper extremity
work capacity in persons with cervical-level spinal cord injury. Arch Phys
Med Rehabil. 2002;83(1):19–23.
134. Tyler TF, et al. The effect of creatine supplementation on strength recovery
after anterior cruciate ligament (ACL) reconstruction: a randomized,
placebo-controlled, double-blind trial. Am J Sports Med. 2004;32(2):383–8.
135. Perret C, Mueller G, Knecht H. Influence of creatine supplementation on
800 m wheelchair performance: a pilot study. Spinal Cord. 2006;44(5):275–9.
136. Kley RA, Vorgerd M, Tarnopolsky MA. Creatine for treating muscle disorders.
Cochrane Database Syst Rev. 2007;1:CD004760.
137. Sullivan PG, et al. Dietary supplement creatine protects against traumatic
brain injury. Ann Neurol. 2000;48(5):723–9.
138. Hausmann ON, et al. Protective effects of oral creatine supplementation on
spinal cord injury in rats. Spinal Cord. 2002;40(9):449–56.
139. Prass K, et al. Improved reperfusion and neuroprotection by creatine in a
mouse model of stroke. J Cereb Blood Flow Metab. 2007;27(3):452–9.
140. Adcock KH, et al. Neuroprotection of creatine supplementation in
neonatal rats with transient cerebral hypoxia-ischemia. Dev Neurosci.
141. Zhu S, et al. Prophylactic creatine administration mediates neuroprotection
in cerebral ischemia in mice. J Neurosci. 2004;24(26):5909–12.
142. Allah Yar R, Akbar A, Iqbal F. Creatine monohydrate supplementation for 10
weeks mediates neuroprotection and improves learning/memory following
neonatal hypoxia ischemia encephalopathy in female albino mice. Brain
143. Rabchevsky AG, et al. Creatine diet supplement for spinal cord injury:
influences on functional recovery and tissue sparing in rats. J Neurotrauma.
144. Freire Royes LF, Cassol G. The effects of Creatine supplementation and physical
exercise on traumatic brain injury. Mini Rev Med Chem. 2016;16(1):29–39.
145. Stockler-Ipsiroglu S, van Karnebeek CD. Cerebral creatine deficiencies:
a group of treatable intellectual developmental disorders. Semin Neurol.
146. Longo N, et al. Disorders of creatine transport and metabolism. Am J Med
Genet C Semin Med Genet. 2011;157C(1):72–8.
147. Nasrallah F, Feki M, Kaabachi N. Creatine and creatine deficiency syndromes:
biochemical and clinical aspects. Pediatr Neurol. 2010;42(3):163–71.
148. Mercimek-Mahmutoglu S, et al. GAMT deficiency: features, treatment, and
outcome in an inborn error of creatine synthesis. Neurology. 2006;67(3):
149. Stromberger C, Bodamer OA, Stockler-Ipsiroglu S. Clinical characteristics and
diagnostic clues in inborn errors of creatine metabolism. J Inherit Metab Dis.
150. Battini R, et al. Arginine:glycine amidinotransferase (AGAT) deficiency in a
newborn: early treatment can prevent phenotypic expression of the disease.
J Pediatr. 2006;148(6):828–30.
151. Stockler-Ipsiroglu S, et al. Guanidinoacetate methyltransferase (GAMT)
deficiency: outcomes in 48 individuals and recommendations for diagnosis,
treatment and monitoring. Mol Genet Metab. 2014;111(1):16–25.
152. Valtonen M, et al. Central nervous system involvement in gyrate atrophy of
the choroid and retina with hyperornithinaemia. J Inherit Metab Dis.
153. Nanto-Salonen K, et al. Reduced brain creatine in gyrate atrophy of the
choroid and retina with hyperornithinemia. Neurology. 1999;53(2):303–7.
154. Heinanen K, et al. Creatine corrects muscle 31P spectrum in gyrate atrophy
with hyperornithinaemia. Eur J Clin Invest. 1999;29(12):1060–5.
155. Vannas-Sulonen K, et al. Gyrate atrophy of the choroid and retina.
A five-year follow-up of creatine supplementation. Ophthalmology. 1985;
156. Sipila I, et al. Supplementary creatine as a treatment for gyrate atrophy of
the choroid and retina. N Engl J Med. 1981;304(15):867–70.
157. Evangeliou A, et al. Clinical applications of creatine supplementation on
paediatrics. Curr Pharm Biotechnol. 2009;10(7):683–90.
158. Verbruggen KT, et al. Global developmental delay in guanidionacetate
methyltransferase deficiency: differences in formal testing and clinical
observation. Eur J Pediatr. 2007;166(9):921–5.
159. Ensenauer R, et al. Guanidinoacetate methyltransferase deficiency:
differences of creatine uptake in human brain and muscle. Mol Genet Metab.
160. Ogborn DI, et al. Effects of creatine and exercise on skeletal muscle of
FRG1-transgenic mice. Can J Neurol Sci. 2012;39(2):225–31.
161. Louis M, et al. Beneficial effects of creatine supplementation in dystrophic
patients. Muscle Nerve. 2003;27(5):604–10.
162. Banerjee B, et al. Effect of creatine monohydrate in improving cellular
energetics and muscle strength in ambulatory Duchenne muscular
dystrophy patients: a randomized, placebo-controlled 31P MRS study.
Magn Reson Imaging. 2010;28(5):698–707.
163. Felber S, et al. Oral creatine supplementation in Duchenne muscular
dystrophy: a clinical and 31P magnetic resonance spectroscopy study.
Neurol Res. 2000;22(2):145–50.
164. Radley HG, et al. Duchenne muscular dystrophy: focus on pharmaceutical
and nutritional interventions. Int J Biochem Cell Biol. 2007;39(3):469–77.
165. Tarnopolsky MA, et al. Creatine monohydrate enhances strength and body
composition in Duchenne muscular dystrophy. Neurology. 2004;62(10):
166. Adhihetty PJ, Beal MF. Creatine and its potential therapeutic value for
targeting cellular energy impairment in neurodegenerative diseases.
Neuromolecular Med. 2008;10(4):275–90.
167. Verbessem P, et al. Creatine supplementation in Huntington’s disease:
a placebo-controlled pilot trial. Neurology. 2003;61(7):925–30.
168. Dedeoglu A, et al. Creatine therapy provides neuroprotection after onset of
clinical symptoms in Huntington’s disease transgenic mice. J Neurochem.
169. Andreassen OA, et al. Creatine increase survival and delays motor
symptoms in a transgenic animal model of Huntington’s disease.
Neurobiol Dis. 2001;8(3):479–91.
170. Ferrante RJ, et al. Neuroprotective effects of creatine in a transgenic mouse
model of Huntington’s disease. J Neurosci. 2000;20(12):4389–97.
171. Matthews RT, et al. Neuroprotective effects of creatine and cyclocreatine in
animal models of Huntington’s disease. J Neurosci. 1998;18(1):156–63.
172. Bender A, et al. Long-term creatine supplementation is safe in aged
patients with Parkinson disease. Nutr Res. 2008;28(3):172–8.
173. Hass CJ, Collins MA, Juncos JL. Resistance training with creatine
monohydrate improves upper-body strength in patients with Parkinson
disease: a randomized trial. Neurorehabil Neural Repair. 2007;21(2):107–15.
174. Bender A, et al. Creatine supplementation in Parkinson disease: a placebo-
controlled randomized pilot trial. Neurology. 2006;67(7):1262–4.
175. Komura K, et al. Effectiveness of creatine monohydrate in mitochondrial
encephalomyopathies. Pediatr Neurol. 2003;28(1):53–8.
176. Tarnopolsky MA, Parise G. Direct measurement of high-energy phosphate compounds
in patients with neuromuscular disease. Muscle Nerve. 1999;22(9):1228–33.
177. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of
creatine monohydrate in patients with mitochondrial cytopathies.
Muscle Nerve. 1997;20(12):1502–9.
178. Andreassen OA, et al. Increases in cortical glutamate concentrations in
transgenic amyotrophic lateral sclerosis mice are attenuated by creatine
supplementation. J Neurochem. 2001;77(2):383–90.
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 16 of 18
179. Choi JK, et al. Magnetic resonance spectroscopy of regional brain
metabolite markers in FALS mice and the effects of dietary creatine
supplementation. Eur J Neurosci. 2009;30(11):2143–50.
180. Derave W, et al. Skeletal muscle properties in a transgenic mouse model for
amyotrophic lateral sclerosis: effects of creatine treatment. Neurobiol Dis.
181. Drory VE, Gross D. No effect of creatine on respiratory distress in
amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron
182. Ellis AC, Rosenfeld J. The role of creatine in the management of
amyotrophic lateral sclerosis and other neurodegenerative disorders. CNS
183. Mazzini L, et al. Effects of creatine supplementation on exercise
performance and muscular strength in amyotrophic lateral sclerosis:
preliminary results. J Neurol Sci. 2001;191(1–2):139–44.
184. Vielhaber S, et al. Effect of creatine supplementation on metabolite levels in
ALS motor cortices. Exp Neurol. 2001;172(2):377–82.
185. Hultman J, et al. Myocardial energy restoration of ischemic damage by
administration of phosphoenolpyruvate during reperfusion. A study in a
paracorporeal rat heart model. Eur Surg Res. 1983;15(4):200–7.
186. Thelin S, et al. Metabolic and functional effects of creatine phosphate in
cardioplegic solution. Studies on rat hearts during and after normothermic
ischemia. Scand J Thorac Cardiovasc Surg. 1987;21(1):39–45.
187. Osbakken M, et al. Creatine and cyclocreatine effects on ischemic
myocardium: 31P nuclear magnetic resonance evaluation of intact heart.
188. Thorelius J, et al. Biochemical and functional effects of creatine phosphate
in cardioplegic solution during aortic valve surgery—a clinical study. Thorac
Cardiovasc Surg. 1992;40(1):10–3.
189. Boudina S, et al. Alteration of mitochondrial function in a model of chronic
ischemia in vivo in rat heart. Am J Physiol Heart Circ Physiol. 2002;282(3):
190. Laclau MN, et al. Cardioprotection by ischemic preconditioning preserves
mitochondrial function and functional coupling between adenine
nucleotide translocase and creatine kinase. J Mol Cell Cardiol. 2001;33(5):
191. Conorev EA, Sharov VG, Saks VA. Improvement in contractile recovery of
isolated rat heart after cardioplegic ischaemic arrest with endogenous
phosphocreatine: involvement of antiperoxidative effect? Cardiovasc Res.
192. Sharov VG, et al. Protection of ischemic myocardium by exogenous
phosphocreatine. I. Morphologic and phosphorus 31-nuclear magnetic
resonance studies. J Thorac Cardiovasc Surg. 1987;94(5):749–61.
193. Anyukhovsky EP, et al. Effect of phosphocreatine and related compounds
on the phospholipid metabolism of ischemic heart. Biochem Med Metab
194. Sharov VG, et al. Protection of ischemic myocardium by exogenous
phosphocreatine (neoton): pharmacokinetics of phosphocreatine, reduction
of infarct size, stabilization of sarcolemma of ischemic cardiomyocytes, and
antithrombotic action. Biochem Med Metab Biol. 1986;35(1):101–14.
195. Gualano B, et al. Creatine supplementation in the aging population: effects
on skeletal muscle, bone and brain. Amino Acids. 2016;48(8):1793–805.
196. Earnest CP, Almada AL, Mitchell TL. High-performance capillary
electrophoresis-pure creatine monohydrate reduces blood lipids in men
and women. Clin Sci (Lond). 1996;91(1):113–8.
197. Deminice R, et al. Creatine supplementation prevents fatty liver in rats fed
choline-deficient diet: a burden of one-carbon and fatty acid metabolism. J
Nutr Biochem. 2015;26(4):391–7.
198. Deminice R, et al. Creatine supplementation prevents
hyperhomocysteinemia, oxidative stress and cancer-induced cachexia
progression in Walker-256 tumor-bearing rats. Amino Acids. 2016;48(8):
199. Lawler JM, et al. Direct antioxidant properties of creatine. Biochem Biophys
Res Commun. 2002;290(1):47–52.
200. Rakpongsiri K, Sawangkoon S. Protective effect of creatine supplementation
and estrogen replacement on cardiac reserve function and antioxidant
reservation against oxidative stress in exercise-trained ovariectomized
hamsters. Int Heart J. 2008;49(3):343–54.
201. Rahimi R, et al. Effects of creatine monohydrate supplementation on
exercise-induced apoptosis in athletes: a randomized, double-blind, and
placebo-controlled study. J Res Med Sci. 2015;20(8):733–8.
202. Deminice R, Jordao AA. Creatine supplementation decreases plasma lipid
peroxidation markers and enhances anaerobic performance in rats. Redox
203. Gualano B, et al. Creatine in type 2 diabetes: a randomized, double-blind,
placebo-controlled trial. Med Sci Sports Exerc. 2011;43(5):770–8.
204. Op’t Eijnde B, et al. Creatine supplementation increases soleus muscle
creatine content and lowers the insulinogenic index in an animal model of
inherited type 2 diabetes. Int J Mol Med. 2006;17(6):1077–84.
205. Alves CR, et al. Creatine-induced glucose uptake in type 2 diabetes: a role
for AMPK-alpha? Amino Acids. 2012;43(4):1803–7.
206. Smith RN, Agharkar AS, Gonzales EB. A review of creatine supplementation
in age-related diseases: more than a supplement for athletes. F1000Res.
207. Patra S, et al. A short review on creatine-creatine kinase system in relation
to cancer and some experimental results on creatine as adjuvant in cancer
therapy. Amino Acids. 2012;42(6):2319–30.
208. Canete S, et al. Does creatine supplementation improve functional capacity
in elderly women? J Strength Cond Res. 2006;20(1):22–8.
209. Candow DG, Chilibeck PD. Effect of creatine supplementation during
resistance training on muscle accretion in the elderly. J Nutr Health Aging.
210. Candow DG, et al. Comparison of creatine supplementation before versus
after supervised resistance training in healthy older adults. Res Sports Med.
211. Candow DG, et al. Low-dose creatine combined with protein during
resistance training in older men. Med Sci Sports Exerc. 2008;40(9):1645–52.
212. Chilibeck PD, et al. Effects of creatine and resistance training on bone
health in postmenopausal women. Med Sci Sports Exerc. 2015;47(8):
213. Neves Jr M, et al. Beneficial effect of creatine supplementation in knee
osteoarthritis. Med Sci Sports Exerc. 2011;43(8):1538–43.
214. Alves CR, et al. Creatine supplementation in fibromyalgia: a randomized,
double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2013;
215. Roitman S, et al. Creatine monohydrate in resistant depression: a
preliminary study. Bipolar Disord. 2007;9(7):754–8.
216. D’Anci KE, Allen PJ, Kanarek RB. A potential role for creatine in drug abuse?
Mol Neurobiol. 2011;44(2):136–41.
217. Toniolo RA, et al. Cognitive effects of creatine monohydrate adjunctive
therapy in patients with bipolar depression: Results from a randomized,
double-blind, placebo-controlled trial. J Affect Disord. 2016.
218. Dechent P, et al. Increase of total creatine in human brain after oral
supplementation of creatine-monohydrate. Am J Physiol. 1999;277(3 Pt 2):
219. Lyoo IK, et al. Multinuclear magnetic resonance spectroscopy of high-
energy phosphate metabolites in human brain following oral
supplementation of creatine-monohydrate. Psychiatry Res. 2003;123(2):87–
220. Pan JW, Takahashi K. Cerebral energetic effects of creatine supplementation
in humans. Am J Physiol Regul Integr Comp Physiol. 2007;292(4):R1745–50.
221. Watanabe A, Kato N, Kato T. Effects of creatine on mental fatigue and
cerebral hemoglobin oxygenation. Neurosci Res. 2002;42(4):279–85.
222. Rae C, et al. Oral creatine monohydrate supplementation improves brain
performance: a double-blind, placebo-controlled, cross-over trial. Proc Biol
223. McMorris T, et al. Creatine supplementation, sleep deprivation, cortisol,
melatonin and behavior. Physiol Behav. 2007;90(1):21–8.
224. McMorris T, et al. Effect of creatine supplementation and sleep deprivation,
with mild exercise, on cognitive and psychomotor performance, mood
state, and plasma concentrations of catecholamines and cortisol.
Psychopharmacology (Berl). 2006;185(1):93–103.
225. Ling J, Kritikos M, Tiplady B. Cognitive effects of creatine ethyl ester
supplementation. Behav Pharmacol. 2009;20(8):673–9.
226. Ostojic SM. Guanidinoacetic acid as a performance-enhancing agent. Amino
227. Ostojic SM, et al. Guanidinoacetic acid versus creatine for improved brain
and muscle creatine levels: a superiority pilot trial in healthy men. Appl
Physiol Nutr Metab. 2016;41(9):1005–7.
228. Ellery SJ, et al. Renal dysfunction in early adulthood following birth asphyxia
in male spiny mice, and its amelioration by maternal creatine
supplementation during pregnancy. Pediatr Res. 2017.
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 17 of 18
229. LaRosa DA, et al. Maternal creatine supplementation during pregnancy
prevents acute and long-term deficits in skeletal muscle after birth asphyxia:
a study of structure and function of hind limb muscle in the spiny mouse.
Pediatr Res. 2016;80(6):852–60.
230. Ellery SJ, Walker DW, Dickinson H. Creatine for women: a review of the
relationship between creatine and the reproductive cycle and female-
specific benefits of creatine therapy. Amino Acids. 2016;48(8):1807–17.
231. Ellery SJ, et al. Dietary creatine supplementation during pregnancy: a study
on the effects of creatine supplementation on creatine homeostasis and
renal excretory function in spiny mice. Amino Acids. 2016;48(8):1819–30.
232. Dickinson H, et al. Creatine supplementation during pregnancy: summary of
experimental studies suggesting a treatment to improve fetal and neonatal
morbidity and reduce mortality in high-risk human pregnancy. BMC
Pregnancy Childbirth. 2014;14:150.
233. Bortoluzzi VT, et al. Co-administration of creatine plus pyruvate prevents the
effects of phenylalanine administration to female rats during pregnancy and
lactation on enzymes activity of energy metabolism in cerebral cortex and
hippocampus of the offspring. Neurochem Res. 2014;39(8):1594–602.
234. Vallet JL, Miles JR, Rempel LA. Effect of creatine supplementation during the
last week of gestation on birth intervals, stillbirth, and preweaning mortality
in pigs. J Anim Sci. 2013;91(5):2122–32.
235. Ellery SJ, et al. Creatine pretreatment prevents birth asphyxia-induced injury
of the newborn spiny mouse kidney. Pediatr Res. 2013;73(2):201–8.
236. Dickinson H, et al. Maternal dietary creatine supplementation does not alter
the capacity for creatine synthesis in the newborn spiny mouse. Reprod Sci.
237. Ireland Z, et al. A maternal diet supplemented with creatine from mid-
pregnancy protects the newborn spiny mouse brain from birth hypoxia.
238. Geller AI, et al. Emergency department visits for adverse events related to
dietary supplements. N Engl J Med. 2015;373(16):1531–40.
239. Zorzela L, et al. Serious adverse events associated with pediatric
complementary and alternative medicine. Eur J Integr Med. 2014;6:467–47.
240. FDA. CFSAN Adverse Event Reporting System (CAERS). 2017. [cited 2017
March 27, 2017]; Available from: https://www.fda.gov/Food/
ComplianceEnforcement/ucm494015.htm. Accessed 18 Apr 2017.
241. Greenwood M, et al. Creatine supplementation patterns and perceived effects
in select division I collegiate athletes. Clin J Sport Med. 2000;10(3):191–4.
242. Hile AM, et al. Creatine supplementation and anterior compartment
pressure during exercise in the heat in dehydrated men. J Athl Train.
243. Poortmans JR, et al. Effect of short-term creatine supplementation on renal
responses in men. Eur J Appl Physiol Occup Physiol. 1997;76(6):566–7.
244. Robinson TM, et al. Dietary creatine supplementation does not affect some
haematological indices, or indices of muscle damage and hepatic and renal
function. Br J Sports Med. 2000;34(4):284–8.
245. Groeneveld GJ, et al. Few adverse effects of long-term creatine
supplementation in a placebo-controlled trial. Int J Sports Med. 2005;26(4):
246. Gualano B, et al. Effects of creatine supplementation on renal function:
a randomized, double-blind, placebo-controlled clinical trial. Eur J Appl
247. Lugaresi R, et al. Does long-term creatine supplementation impair kidney
function in resistance-trained individuals consuming a high-protein diet?
J Int Soc Sports Nutr. 2013;10(1):26.
248. Farquhar WB, Zambraski EJ. Effects of creatine use on the athlete’s kidney.
Curr Sports Med Rep. 2002;1(2):103–6.
249. Thorsteinsdottir B, Grande JP, Garovic VD. Acute renal failure in a young
weight lifter taking multiple food supplements, including creatine
monohydrate. J Ren Nutr. 2006;16(4):341–5.
250. Kuehl K, Goldberg L, Elliot D, Renal insufficiency after creatine
supplementation in a college football athlete (Abstract). Med Sci Sports
251. Pritchard NR, Kalra PA. Renal dysfunction accompanying oral creatine
supplements. Lancet. 1998;351(9111):1252–3.
252. Barisic N, et al. Effects of oral creatine supplementation in a patient with
MELAS phenotype and associated nephropathy. Neuropediatrics. 2002;33(3):
253. Juhn MS, Tarnopolsky M. Potential side effects of oral creatine
supplementation: a critical review. Clin J Sport Med. 1998;8(4):298–304.
254. Juhn MS. Oral creatine supplementation: separating fact from hype. Phys Sportsmed.
255. Benzi G. Is there a rationale for the use of creatine either as nutritional
supplementation or drug administration in humans participating in a sport?
Pharmacol Res. 2000;41(3):255–64.
256. Benzi G, Ceci A. Creatine as nutritional supplementation and medicinal
product. J Sports Med Phys Fitness. 2001;41(1):1–10.
257. Poortmans JR, Francaux M. Long-term oral creatine supplementation does
not impair renal function in healthy athletes. Med Sci Sports Exerc. 1999;
258. Francaux M, et al. Effect of exogenous creatine supplementation on muscle
PCr metabolism. Int J Sports Med. 2000;21(2):139–45.
259. Poortmans JR, Francaux M. Adverse effects of creatine supplementation:
fact or fiction? Sports Med. 2000;30(3):155–70.
260. Ferreira LG, et al. Effects of creatine supplementation on body composition
and renal function in rats. Med Sci Sports Exerc. 2005;37(9):1525–9.
261. Baracho NC, et al. Study of renal and hepatic toxicity in rats supplemented
with creatine. Acta Cir Bras. 2015;30(5):313–8.
262. Gualano B, et al. Creatine supplementation does not impair kidney function
in type 2 diabetic patients: a randomized, double-blind, placebo-controlled,
clinical trial. Eur J Appl Physiol. 2011;111(5):749–56.
263. Taes YE, et al. Creatine supplementation does not decrease total plasma
homocysteine in chronic hemodialysis patients. Kidney Int. 2004;66(6):2422–8.
264. Shelmadine BD, et al. The effects of supplementation of creatine on total
homocysteine. J Ren Nurs. 2012;4(6):278–83.
265. Shelmadine BD, et al. Effects of thirty days of creatine supplementation on
total homocysteine in a pilot study of end-stage renal disease patients.
J Ren Nurs. 2012;4(4):6–11.
266. Pline KA, Smith CL. The effect of creatine intake on renal function.
Ann Pharmacother. 2005;39(6):1093–6.
267. Persky AM, Rawson ES. Safety of creatine supplementation. Subcell
268. Gualano B, et al. In sickness and in health: the widespread application of
creatine supplementation. Amino Acids. 2012;43(2):519–29.
269. Williams MH. Facts and fallacies of purported ergogenic amino acid
supplements. Clin Sports Med. 1999;18(3):633–49.
• We accept pre-submission inquiries
• Our selector tool helps you to ﬁnd the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research
Submit your manuscript at
Submit your next manuscript to BioMed Central
and we will help you at every step:
Kreider et al. Journal of the International Society of Sports Nutrition (2017) 14:18 Page 18 of 18